Dermatol. praxi. 2016;10(1):24-27 | DOI: 10.36290/der.2016.006

Seborrhoeic dermatitis, differential diagnosis and treatment in the practice

MUDr. Naděžda Vojáčková
Dermatovenerologická ambulance Praha

Seborrhoeic dermatitis is among common skin conditions with a chronically recurrent course, most frequently occurring in the face and hairy part of the head. The differential diagnosis must include perioral dermatitis, rosacea, atopic eczema, psoriasis, microbial eczema, mycoses, and other less frequent entities. The treatment is usually local using external agents with antifungal, antimicrobial, and anti-inflammatory effects.

Keywords: seborrhoeic dermatitis, differential diagnosis, treatment

Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáčková N. Seborrhoeic dermatitis, differential diagnosis and treatment in the practice. Dermatol. praxi. 2016;10(1):24-27. doi: 10.36290/der.2016.006.
Download citation

References

  1. Kojanová M, Šuková T, Štork J. Dermatitis seborrhoica. Čes-slov Derm 2005; 80(5) p. 261-269.
  2. Buchvald D. Lipofilné kvasinky rodu Malassezia a choroby kože I. Seboroická dermatitida. Epidemiol. Mikrobiol. Imunol. 2010; 59(3): 119-125. Go to PubMed...
  3. Lallas A, Giacomel J, Argenziano G, et al. Dermoscopy in General Dermatology: Practical Tips for the Clinician. Br J Dermat, 2014; 170(3) p. 514-526. Go to original source... Go to PubMed...
  4. Čapková Š. Nejčastější kožní choroby v dětském věku a jejich léčba. Derm pro praxi, 2009; 3, p. 119-124.
  5. Naldi L, Diphoorn J. Seborrhoeic dermatitis of the scalp. BMJ Clin Evid, 2015; 27, pii: 1713.
  6. Katsambas A, Antoniou CH, Frangouli E, et al. A double-blind trial of treatment of seborrheic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol. 1989; 121: p. 353-357. Go to original source... Go to PubMed...
  7. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006; 5(7): p. 646-650. Go to PubMed...
  8. Rosso JD. Adult Seborrheic Dermatitis. A Status Report on Practical Topical Management. Clin Aest Derm, 2011; 4(5): p. 32-38.
  9. Goldenberg G. Optimizing Treatment Aproaches in Seborrheic Dermatitis. Clin Aest Derm, 2012; 6(2): p. 44-49.
  10. Viktorinová M. Přehled lokálních kortikosteroidů v dermatologii 2. Rozdělení lokálních kortikosteroidů registrovaných v ČR podle terapeutické účinnosti. Klin Farmakol Farm 2007; 21: 36-41.
  11. Kim HO, Yang YS, Ko HC. Maintenance Therapy of Facial Seborrheic Dermatitis with 0,1 % Tacrolimus Ointment. Ann Dermatol, 2015; 27(5): p. 523-530. Go to original source... Go to PubMed...
  12. Pirkhammer D, Seeber A, Hönigsmann H, et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol, 2000; 143(5): p. 964-968. Go to original source... Go to PubMed...
  13. Vena GA, Micali G, Santoianni P, et al. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J of immunopathology and pharmacology 2005; 18(4): p. 745-753. Go to original source... Go to PubMed...
  14. Alizadeh N, Monadi Nori H, Golchi J, et al. Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis. Dermatol Res Prac, 2014, Article ID 705402, 5 pages http://dx.doi.org/10.1155/2014/705402. Go to original source... Go to PubMed...
  15. Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol. 2005; 19(2): p. 172-175. Go to original source... Go to PubMed...
  16. Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial. Am J Clin Derm, 2015; 16(5): p. 431-437. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.